With over 35 years in pharmaceutical and bioscience industries, Lusia Guthrie is an experienced executive and medtech entrepreneur, with strong leadership skills and international industry networks. She started her career as a Medical Laboratory Scientist before joining the manufacturing division of pharmaceutical company FH Faulding & Co. Lusia then went on to co-found medical technology innovation company LBT Innovations Limited (ASX: LBT) where she served as Chief Executive Officer and Managing Director before retiring late last year.
Earlier this year, Lusia acted as interim CEO during BioMelbourne Network CEO, Dr Krystal Evans,’ parental leave period. Her involvement in the executive management and operations of BioMelbourne Network (the Network) will augment the wealth of commercial experience that Lusia brings to the organisation.
Lusia has a passion and proven track record in bringing innovative products to global markets, embracing the entire process from company formation, capital raising and concept development to product launch. She has particular experience and ongoing interest in the development and commercialization of new healthcare products that embrace automation, robotics, machine learning and artificial intelligence.
Now in a new chapter of her career, Lusia is pursuing Board directorship as a means of sharing her knowledge, experiences and networks. She is currently Chairman of Clever Culture Systems AG, LBT’s joint venture based in Zurich and is a Board member of ANDHealth. She holds Industry Advisory Committee positions with the Australian Centre for Visual Technology (ACVT) at the University of Adelaide and the Australian Regenerative Medicine Institute (ARMI) at Monash University. Lusia recently won a place in the Australian Institute of Company Directors (AICD) Chair’s Mentoring Program and will be honing her skills in this area over the coming year.